Ajanta Pharma Q2 FY26: Profit up 20%, ₹28 dividend set

Ajanta Pharma’s stock was trading at ₹3,058.00 on NSE at 11:21 IST on 17 Mar 2026, up ₹103.90 or 3.52% for the day, as investors tracked the company’s latest financial performance and dividend actions. The move came alongside fresh operating updates that highlighted double-digit growth in quarterly revenue and profit, plus a declared interim dividend.

The company’s snapshot valuation metrics in the provided data include a market capitalisation of ₹36,882 crore, a P/E ratio of 35.8, and a dividend yield of 1.07%. Other listed indicators include ROA of 24.52%, operating profit margin of 30.65%, and a current ratio of 2.65.

Share price action and trading range

On 17 Mar 2026 (11:21 IST), Ajanta Pharma’s intraday high was ₹3,071.60 and intraday low was ₹2,959.00, with the stock last quoted at ₹3,058.00. Another price snapshot in the data set shows AJANTPHARM at ₹2,831.50 at 16:00 IST on 06 Feb 2026, up 0.50% for that session.

The dataset also includes 52-week reference points. One section shows a 52-week high of ₹3,180.95 dated 31-Oct-2024. Another section lists 52-week high as ₹3,280.00 and 52-week low as ₹2,329.90. Since these figures come from different parts of the provided text, readers should treat them as separate published data points rather than a single reconciled range.

Q2 FY26 results: profit rises 20%, revenue up 14%

Ajanta Pharma reported consolidated net profit of ₹260 crore for the second quarter of FY26, up 20% from ₹216 crore in the same quarter last year. Consolidated revenue from operations for the quarter rose 14% year-on-year to ₹1,354 crore from ₹1,187 crore.

The company also reported EBITDA of ₹328 crore for the quarter, showing a 5% increase, with EBITDA margin reported at 24% in one section of the provided text. Separately, the dataset also states that Ajanta Pharma reported a “strong EBITDA margin of 25% in the quarter”. These are the two margin figures explicitly present in the material.

Business drivers: India branded generics and US generics

Ajanta Pharma attributed the quarter’s performance to growth across key operating segments. Its branded generics business in India grew 12% to ₹432 crore. The company also highlighted a 48% surge in its US generics business, which contributed ₹344 crore in revenue.

The text further states that Ajanta Pharma’s Indian branded generics business outperformed the overall Indian Pharmaceutical Market (IPM), exceeding its growth by 32%, with ophthalmology and dermatology called out as the stronger segments.

H1 FY26: double-digit growth continues

For the first half of FY26, Ajanta Pharma reported consolidated revenue of ₹2,656 crore, up 14%. Consolidated net profit for H1 FY26 was ₹516 crore, up 12%.

These H1 numbers provide context that the Q2 performance was not presented as a one-off quarter in the provided text, but as part of a broader first-half trend of double-digit increases in revenue and profit.

Interim dividend: ₹28 per share, record date in November

Ajanta Pharma’s Board approved the first interim dividend for FY26 at ₹28 per equity share (face value ₹2). The total payout for this dividend is stated as ₹349.82 crore.

The record date is 10 Nov 2025, and the payment is scheduled for on or after 20 Nov 2025. Corporate action entries in the dataset also list a dividend of ₹28 per share with ex-date 10 Nov 2025, and another dividend of ₹28 per share with ex-date 06 Nov 2024.

Corporate actions history mentioned in the dataset

Beyond the latest dividend, the text includes a list of past corporate actions such as buybacks and bonus issuance. Items explicitly listed include: interim dividend of ₹28 per share (06-Nov-2024), buyback (30-May-2024), interim dividend of ₹26 per share (08-Feb-2024), interim dividend of ₹10 per share plus special dividend of ₹15 per share (04-Aug-2023), buyback (24-Mar-2023), interim dividend of ₹7 per share (11-Nov-2022), and bonus of 1:2 (22-Jun-2022).

Separately, an annual-review style section notes consolidated revenue from operations of ₹4,208.71 crore (up 12% over the previous year), consolidated profit after tax of ₹816.17 crore (up 39%), and exports contributing 68% of revenue. It also references two interim dividends of ₹25 and ₹26, with total pay-outs of ₹315 crore and ₹327 crore, and points to the company’s stated dividend distribution policy.

Key numbers at a glance

Quarterly financial results table (converted to ₹ crore)

The dataset provides “Financial Results (Amount in Lakhs.)”. Converted below using 1 lakh = 0.01 crore.

Market impact: what the numbers imply for investors

The combination of a 14% year-on-year rise in quarterly revenue and a 20% increase in quarterly net profit is typically interpreted by markets as confirmation of operational momentum, especially when accompanied by segment-level growth disclosures. In Ajanta Pharma’s case, the provided data highlights growth in India branded generics (₹432 crore) and US generics (₹344 crore), which helps investors connect headline revenue to business drivers.

The interim dividend of ₹28 per share and the stated total payout of ₹349.82 crore also adds a shareholder-return component to the broader earnings narrative. The dataset additionally notes a latest dividend payout ratio of 78.67% and a 3-year average dividend payout ratio of 35.01%, framing dividend outgo in the context of reported payout behaviour.

Why this update matters in the pharma context

Ajanta Pharma’s update stands out because it combines three elements: growth in consolidated revenue, growth in consolidated profit, and a confirmed interim dividend schedule with record and payment timelines. The company’s note that its India branded generics business exceeded IPM growth by 32%, with strength in ophthalmology and dermatology, gives additional colour on where growth is being seen.

At the same time, investors typically track valuation and balance-sheet indicators alongside results. The dataset lists a P/E ratio of 35.8, operating profit margin of 30.65%, and current ratio of 2.65. These numbers are often used by market participants to compare pharma companies on profitability and liquidity, alongside revenue mix indicators such as the export contribution of 68% mentioned in the annual-review section.

Conclusion

Ajanta Pharma’s disclosed Q2 FY26 numbers show revenue from operations of ₹1,354 crore and net profit of ₹260 crore, alongside an interim dividend of ₹28 per share with a 10 Nov 2025 record date and payment on or after 20 Nov 2025. The next investor focus points, based on the provided information, remain the execution across India branded generics and US generics and the follow-through on the announced dividend payment timeline.